Antitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice Model
Adjuvants, Immunologic
/ therapeutic use
Animals
Autophagy
Beclin-1
/ metabolism
CHO Cells
Cell Proliferation
Cricetinae
Cricetulus
Cytokines
/ metabolism
Cytotoxicity, Immunologic
Disease Models, Animal
Female
HEK293 Cells
Humans
Mice, Inbred C57BL
Papillomavirus Infections
/ drug therapy
Papillomavirus Vaccines
/ immunology
T-Lymphocytes
/ metabolism
Vaccines, DNA
/ immunology
Adjuvants
Autophagy
Beclin-1
Journal
Iranian biomedical journal
ISSN: 2008-823X
Titre abrégé: Iran Biomed J
Pays: Iran
ID NLM: 9814853
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
entrez:
21
5
2019
pubmed:
21
5
2019
medline:
18
2
2020
Statut:
ppublish
Résumé
There is a growing interest in development of an effective adjuvant system for improving DNA vaccines. Recent findings have confirmed an important role for autophagy in both innate and adaptive immunity. The current study was undertaken to determine the efficacy of autophagy induction with Beclin-1, as a novel adjuvant system, in mice immunized with human papilloma virus (HPV) DNA vaccine. To determine whether autophagy induction with Beclin-1 enhances the efficacy of HPV DNA vaccine, female C57BL/6 mice were challenged with TC-1 tumor cells and were immunized three times at one-week intervals. Two weeks after the final immunization, the mice were sacrificed, and the antitumor effects were assessed by measurement of lymphocyte proliferation, cytotoxicity, cytokine production, and tumor regression. Beclin-1 in combination with HPV-16 DNA vaccine encoding the E7 antigen induced a higher level of lymphocyte proliferation and cytotoxicity than the DNA vaccine alone. The novel combination increased the production of IFN-γ and highly inhibited tumor progression in comparison with DNA vaccine alone. Administration of Beclin-1, as an autophagy inducer, with HPV DNA vaccine produces antitumor effects, providing an effective adjuvant for the induction of a strong antitumor immune response.
Sections du résumé
Background
There is a growing interest in development of an effective adjuvant system for improving DNA vaccines. Recent findings have confirmed an important role for autophagy in both innate and adaptive immunity. The current study was undertaken to determine the efficacy of autophagy induction with Beclin-1, as a novel adjuvant system, in mice immunized with human papilloma virus (HPV) DNA vaccine.
Methods
To determine whether autophagy induction with Beclin-1 enhances the efficacy of HPV DNA vaccine, female C57BL/6 mice were challenged with TC-1 tumor cells and were immunized three times at one-week intervals. Two weeks after the final immunization, the mice were sacrificed, and the antitumor effects were assessed by measurement of lymphocyte proliferation, cytotoxicity, cytokine production, and tumor regression.
Results
Beclin-1 in combination with HPV-16 DNA vaccine encoding the E7 antigen induced a higher level of lymphocyte proliferation and cytotoxicity than the DNA vaccine alone. The novel combination increased the production of IFN-γ and highly inhibited tumor progression in comparison with DNA vaccine alone.
Conclusion
Administration of Beclin-1, as an autophagy inducer, with HPV DNA vaccine produces antitumor effects, providing an effective adjuvant for the induction of a strong antitumor immune response.
Substances chimiques
Adjuvants, Immunologic
0
Beclin-1
0
Cytokines
0
Papillomavirus Vaccines
0
Vaccines, DNA
0
Types de publication
Journal Article
Langues
eng
Pagination
388-94Références
Autophagy. 2016 Oct 2;12(10):1962-1964
pubmed: 27532519
J Gen Virol. 2012 Apr;93(Pt 4):681-91
pubmed: 22323530
Front Immunol. 2016 May 10;7:167
pubmed: 27242780
J Clin Invest. 2015 Jan;125(1):14-24
pubmed: 25654546
Curr Issues Mol Biol. 2017;22:17-40
pubmed: 27648581
BioDrugs. 2010 Apr 1;24(2):109-29
pubmed: 20199126
Cancer Chemother Pharmacol. 2018 Dec;82(6):913-922
pubmed: 30182146
Nat Cell Biol. 2014 Jun;16(6):495-501
pubmed: 24875736
Drugs Today (Barc). 2018 May;54(5):315-333
pubmed: 29911696
J Biomed Sci. 2014 Jul 31;21:69
pubmed: 25077570
Vaccine. 2013 Jan 21;31(5):784-90
pubmed: 23228812
Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78
pubmed: 8876633
Microb Pathog. 2013 May;58:55-65
pubmed: 23164805
Immunity. 2010 Feb 26;32(2):227-39
pubmed: 20171125
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Immunity. 2007 Jan;26(1):79-92
pubmed: 17182262
Immunol Cell Biol. 2012 Nov;90(10):978-82
pubmed: 22929180
Clin Cancer Res. 2016 May 15;22(10):2329-34
pubmed: 27016309
Vaccine. 2017 Feb 1;35(5):808-813
pubmed: 28049588
Semin Cancer Biol. 2013 Oct;23(5):391-6
pubmed: 23541679
Expert Opin Emerg Drugs. 2012 Dec;17(4):469-92
pubmed: 23163511
IUBMB Life. 2018 Mar;70(3):207-214
pubmed: 29369472
Expert Rev Vaccines. 2013 Mar;12(3):271-83
pubmed: 23496667
Vaccine. 2014 Apr 25;32(20):2308-14
pubmed: 24631071
EMBO J. 2015 Oct 1;34(19):2391-2
pubmed: 26334538
J Biotechnol. 2012 Dec 31;162(2-3):171-82
pubmed: 22981627
J Cell Biol. 2010 Jun 14;189(6):925-35
pubmed: 20548099
Nat Cell Biol. 2013 Jul;15(7):741-50
pubmed: 23685627
Vaccines (Basel). 2014 Jan 13;2(1):89-106
pubmed: 26344468
Arch Pharm Res. 2017 Sep;40(9):1050-1063
pubmed: 28875439
Artif Cells Nanomed Biotechnol. 2015;43(6):366-72
pubmed: 24641772
Hepatology. 2009 Jan;49(1):60-71
pubmed: 19065679
J Immunol. 2013 Sep 1;191(5):2526-37
pubmed: 23894198